Recent News

• 04.21.2025 - Chemomab Therapeutics to Present Nebokitug Clinical Data at Upcoming Scientific Conferences
• 04.21.2025 - Chemomab Therapeutics to Present Nebokitug Clinical Data at Upcoming Scientific Conferences
• 04.15.2025 - Chemomab Announces New Medical and Clinical Appointments
• 04.15.2025 - Chemomab Announces New Medical and Clinical Appointments
• 03.27.2025 - Chemomab Reports Positive Results in Nebokitug Phase 2 PSC Open Label Extension Trial Showing Continued Broad and Substantial Improvements in Key Liver Biomarkers
• 03.27.2025 - Chemomab Reports Positive Results in Nebokitug Phase 2 PSC Open Label Extension Trial Showing Continued Broad and Substantial Improvements in Key Liver Biomarkers
• 03.06.2025 - New Data Presented at CORA 2025 Conference Highlights Clinical Potential of Chemomab’s Nebokitug in Systemic Sclerosis
• 03.03.2025 - Chemomab Therapeutics Announces Year End and Fourth Quarter 2024 Financial Results and Provides a Corporate Update
• 03.03.2025 - Chemomab Therapeutics Announces Year End and Fourth Quarter 2024 Financial Results and Provides a Corporate Update
• 02.19.2025 - Chemomab Completes Successful End-of-Phase 2 Meeting and Aligns with FDA on Clear and Efficient Path to Potential Regulatory Approval for Nebokitug (CM-101) in Primary Sclerosing Cholangitis

Recent Filings

• 04.15.2025 - EX-99.1 EX-99.1
• 04.15.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 04.10.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 04.04.2025 - 20-F Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
• 03.27.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 03.27.2025 - EX-99.1 EX-99.1
• 03.20.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 03.03.2025 - EX-99.1 EX-99.1
• 03.03.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]